Pasar al contenido principal

-

IJCI-2014-20723

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Juan de la Cierva Incorporación
Año convocatoria 2014
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario FUNDACIO INSTITUT HOSPITAL DEL MAR D'INVESTIGACIONS MEDIQUES
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells

  • Cebrià Costa, Joan Pau
  • Serra Bardenys, Gemma
  • Querol, J
  • Cosín, M
  • Verde, Gaetano
  • Nuciforo, Paolo Giovanni
  • Arribas López, Joaquin Vicente
  • Peiro Sales, Sandra
  • Bernadó Morales, Cristina
  • Pascual Reguant, Laura
  • Gonzalez-Perez, Abel
  • Rodilla Benito, Verónica
Cromosomes; Marcadors pronòstics, Cromosomas; Marcadores de pronóstico, Chromosomes; Prognostic markers, Oxidation of H3 at lysine 4 (H3K4ox) by lysyl oxidase-like 2 (LOXL2) generates an H3 modification with an unknown physiological function. We find that LOXL2 and H3K4ox are higher in triple-negative breast cancer (TNBC) cell lines and patient-derived xenografts (PDXs) than those from other breast cancer subtypes. ChIP-seq revealed that H3K4ox is located primarily in heterochromatin, where it is involved in chromatin compaction. Knocking down LOXL2 reduces H3K4ox levels and causes chromatin decompaction, resulting in a sustained activation of the DNA damage response (DDR) and increased susceptibility to anticancer agents. This critical role that LOXL2 and oxidized H3 play in chromatin compaction and DDR suggests that functionally targeting LOXL2 could be a way to sensitize TNBC cells to conventional therapy., This work was supported by grants from Instituto de Salud Carlos III (ISCIII) FIS/FEDER (PI12/01250; CP08/00223; PI16/00253; and CB16/12/00449), MINECO (SAF2013-48849-C2-1-R) to SP, BFU2015-68354 to THS, Breast Cancer Research Foundation (BCRF-17-008) to JA, AGL2014-52395-C2-2-R to DA, Worldwide Cancer Research, Red Temática de Investigación Cooperativa en Cáncer (RD012/0036/005), Fundación Científica de la Asociación Española contra el Cáncer, and Fundació La Marató TV3. THS was supported by institutional funding (MINECO) through the Centres of Excellence Severo Ochoa award and the CERCA Programme of the Catalan Government, and SS-B, by a Fundació La Caixa fellowship. We thank La Caixa Foundation and Cellex Foundation for provide research facilities and equipment. GV has received funding from the MINECO (a “Juan de la Cierva Incorporation” fellowship; IJCI-2014-20723). SP was a recipient of a Miguel Servet contract (ISCIII/FIS), and AI, JPC-C, LP-G, and GS-B are supported by contracts from Worldwide Cancer Research, Fundació La Marató TV3, Fundació FERO, and a FI Fellowship from the Generalitat de Catalunya, respectively.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells

  • Cebrià Costa, Joan Pau|||0000-0002-3628-2973
  • Pascual Reguant, Laura|||0000-0003-2361-1392
  • Gonzalez-Perez, Abel|||0000-0002-8582-4660
  • Serra-Bardenys, Gemma
  • Querol, Jessica|||0000-0002-0527-759X
  • Cosín Tomás, Marc
  • Verde, Gaetano|||0000-0003-4768-0165
  • Aiese Cigliano, Riccardo|||0000-0002-9058-6994
  • Sanseverino, Walter|||0000-0003-3324-5912
  • Segura-Bayona, Sandra|||0000-0001-7788-9889
  • Iturbide, Ane
  • Andreu Martínez, David|||0000-0002-6317-6666
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Bernadó Morales, Cristina|||0000-0003-1376-0407
  • Rodilla, Verónica|||0000-0003-0512-4179
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Yélamos, José|||0000-0003-1195-1496
  • Garcia de Herreros, Antonio|||0000-0001-5270-0808
  • Stracker, Travis H.|||0000-0002-8650-2081
  • Peiró, Sandra|||0000-0001-9519-3877
Oxidation of H3 at lysine 4 (H3K4ox) by lysyl oxidase-like 2 (LOXL2) generates an H3 modification with an unknown physiological function. We find that LOXL2 and H3K4ox are higher in triple-negative breast cancer (TNBC) cell lines and patient-derived xenografts (PDXs) than those from other breast cancer subtypes. ChIP-seq revealed that H3K4ox is located primarily in heterochromatin, where it is involved in chromatin compaction. Knocking down LOXL2 reduces H3K4ox levels and causes chromatin decompaction, resulting in a sustained activation of the DNA damage response (DDR) and increased susceptibility to anticancer agents. This critical role that LOXL2 and oxidized H3 play in chromatin compaction and DDR suggests that functionally targeting LOXL2 could be a way to sensitize TNBC cells to conventional therapy.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells

  • Cebrià Costa, Joan Pau
  • Serra Bardenys, Gemma
  • Querol, J
  • Cosín, M
  • Verde, Gaetano
  • Nuciforo, Paolo Giovanni
  • Arribas López, Joaquin Vicente
  • Peiro Sales, Sandra
  • Bernadó Morales, Cristina
  • Pascual Reguant, Laura
  • Gonzalez-Perez, Abel
  • Rodilla Benito, Verónica
Cromosomes; Marcadors pronòstics, Cromosomas; Marcadores de pronóstico, Chromosomes; Prognostic markers, Oxidation of H3 at lysine 4 (H3K4ox) by lysyl oxidase-like 2 (LOXL2) generates an H3 modification with an unknown physiological function. We find that LOXL2 and H3K4ox are higher in triple-negative breast cancer (TNBC) cell lines and patient-derived xenografts (PDXs) than those from other breast cancer subtypes. ChIP-seq revealed that H3K4ox is located primarily in heterochromatin, where it is involved in chromatin compaction. Knocking down LOXL2 reduces H3K4ox levels and causes chromatin decompaction, resulting in a sustained activation of the DNA damage response (DDR) and increased susceptibility to anticancer agents. This critical role that LOXL2 and oxidized H3 play in chromatin compaction and DDR suggests that functionally targeting LOXL2 could be a way to sensitize TNBC cells to conventional therapy., This work was supported by grants from Instituto de Salud Carlos III (ISCIII) FIS/FEDER (PI12/01250; CP08/00223; PI16/00253; and CB16/12/00449), MINECO (SAF2013-48849-C2-1-R) to SP, BFU2015-68354 to THS, Breast Cancer Research Foundation (BCRF-17-008) to JA, AGL2014-52395-C2-2-R to DA, Worldwide Cancer Research, Red Temática de Investigación Cooperativa en Cáncer (RD012/0036/005), Fundación Científica de la Asociación Española contra el Cáncer, and Fundació La Marató TV3. THS was supported by institutional funding (MINECO) through the Centres of Excellence Severo Ochoa award and the CERCA Programme of the Catalan Government, and SS-B, by a Fundació La Caixa fellowship. We thank La Caixa Foundation and Cellex Foundation for provide research facilities and equipment. GV has received funding from the MINECO (a “Juan de la Cierva Incorporation” fellowship; IJCI-2014-20723). SP was a recipient of a Miguel Servet contract (ISCIII/FIS), and AI, JPC-C, LP-G, and GS-B are supported by contracts from Worldwide Cancer Research, Fundació La Marató TV3, Fundació FERO, and a FI Fellowship from the Generalitat de Catalunya, respectively.